OTC Markets EXMKT - Delayed Quote USD

PharmaCom BioVet, Inc. (PHMB)

Compare
0.0001
0.0000
(0.00%)
At close: January 22 at 3:00:00 PM EST

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Ira Frohman President, Secretary, Treasurer and Director -- -- --
Mr. Steve A. York Vice President of Operations & Marketing and Director -- -- --
Mr. Dino Paolucci Jr. Vice President of D Mecatronics and Director -- -- --

PharmaCom BioVet, Inc.

6040-A Six Forks Road
Suite 135
Raleigh, NC 27609
United States
919 604 4887
Sector: 
Healthcare

Description

PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. The company focuses on developing bone marrow transplantation and other cancer treatment procedures to benefit companion animals that are diagnosed with lymphoma, other different types of cancers, and other diseases that are incurable. It has licensed a series of proprietary devices and compounds that would reduce suffering in animals with cancer. The company was formerly known as ABV Gold Inc. and changed its name to PharmaCom BioVet, Inc. in August 2008. PharmaCom BioVet, Inc. was incorporated in 1995 and is headquartered in Raleigh, North Carolina.

Corporate Governance

PharmaCom BioVet, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events